Studies adults with triple negative B-cell acute lymphoblastic leukemia
Observes adults with triple negative B-cell acute lymphoblastic leukemia, studying their disease features.
Plain-language title generated from the registry record
Registry title: "Triple Negative" Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL
Key facts
- Where
- Meldola, Ravenna, and Rimini, ItalySee the 3 sites
Where in Italy
- Irst-IrccsMeldola, ItalyTaking people
- Ospedale S. Maria delle Croci RAVENNARavenna, ItalyTaking people
- Ospedale "Infermi"Rimini, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- Trial code
- NCT06919393
- Record updated
- 9 April 2025
- Original description
It is a multicenter, non-interventional, non pharmacological, translational, prospective study. Any decision about drug administration is made by the physician based on his clinical judgment in the context of clinical practice, independently from the decision to include the patient in the study.Read full original descriptionShow less
"Triple Negative" Adult B-cell Acute Lymphoblastic Leukemia: Molecular Characterization, Identification and New Stratification
It is a multicenter, non-interventional, non pharmacological, translational, prospective study. Any decision about drug administration is made by the physician based on his clinical judgment in the context of clinical practice, independently from the decision to include the patient in the study.
Inclusion: Participant is willing and able to give informed consent for participation in the study; Patients with new diagnosis and/or relapse/s of primary or secondary B-ALL; Negative for BCR-ABL1 t(9;22); TCF3-PBX1 t(1;19); MLL-AF4 t(4;11) rearrangements; Participant is willing and able to give informed consent for participation in the study; Male or Female, aged >18 years; Availability of clinical data.
Exclusion: Age < 18 years; B-ALL positive for BCR-ABL1 t(9;22); TCF3-PBX1 t(1;19); MLL-AF4 t(4;11) rearrangements; Low blast percentage (<70%) samples could be excluded for molecular evaluations, not for cytofluorimetric analyses.